Handbook of Pharmaceutical Science and Technology Studies

Edited by Conor M.W. Douglas, Associate Professor, Department of Science, Technology and Society, York University, Canada, Susi Geiger, Professor of Markets, Organisations and Society, School of Business, University College Dublin, Tineke Kleinhout-Vliek, Researcher, School of Business, University College Dublin, Ireland, Paul Martin, Professor, School of Sociological Studies, Politics and International Relations, University of Sheffield, UK and Sarah Wadmann, Senior Researcher, VIVE - Danish Center for Social Science Research, Denmark

• ContentsIntroduction to the Handbook of Pharmaceutical Science and Technology Studies xviiiConor Douglas, Susi Geiger, Tineke Kleinhout-Vliek, Paul Martin and Sarah WadmannPART I THE DEVELOPMENT OF PHARMACEUTICALS1 The production of pharmaceutical knowledge 2Paul Martin2 Myths about innovation in the pharmaceutical industry 8Joel Lexchin3 From bench to bedside and back again 25Joshua R. Moon4 Population-making in the regulatory arenas of clinical trials 41Jakob Wested5 The dynamics of “Orphanization” and the move towards precisionmedicine 57Paul Martin, Andy Bartlett, Jin Ding, Matthew S. Hanchard and Eva Hilberg6 How can innovation policy address “market failures” in the development ofnovel medicines? 70Jin Ding, Michael M. Hopkins and Jorge Mestre-Ferrandiz7 Social pharmaceutical innovation (SPIN): A sensitizing concept forchallenges in rare diseases 90Conor M. W. Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, WouterBoon, Claudio Cordovil Oliveira, Ellen Moors, Shir Grunebaum andFernando AithPART II MANUFACTURING AND PRODUCTION OF PHARMACEUTICALS8 Introduction to Part II: The political economy of the manufacturing andproduction of pharmaceuticals 111Conor M. W. Douglas9 Vaccine nationalism beyond COVID-19: Prior dynamics and subsequenteffects 121Vesna Trifunović, Jan Hendriks and Stuart Blume10 Peripheral vaccine promises in Latin America: Expectations, coalitions,and sovereignty 138Gabriela Bortz, María Cecilia Sanmartin and Elize Massard da Fonseca11 A world of generics: The manufacturing and circulation of genericmedicines worldwide 159Etienne Nouguez12 Manufacturing and production of advanced therapies: A case of blurredboundaries 172Michael Morrison, Isabel Briz Hernandez and Conor M. W. Douglas13 Between activism and entrepreneurship: Challenging epistemic authoritythrough pharmaceutical peer production 190Bianca Jansky, Shane O’Donnell, Henriette Langstrup and Muireann Quigley14 Drugged ecologies: The case of pharmaceutical pollution 204Gergely MohácsiPART III PHARMACEUTICAL MARKETIZATION: HOW MARKETS INPHARMA ARE MADE AND SHAPED15 Pharmaceutical marketization: How markets in pharma are made andshaped 223Susi Geiger16 The financialization of the pharmaceutical industry: the case of NovoNordisk’s Wegovy 232Prof Joan Busfield17 “The price that we pay is not the real price of the medicine”: How thepharmaceutical price architecture facilitates financial accumulation 249Susi Geiger and Théo Bourgeron18 Medical writing, the marketing playbook, and the pharmaceutical industry 264Maud Bernisson, Willem Halffman and Sergio Sismondo19 The work digital does in pharmaceutical markets 281Gemma Milne and Mathias Møllebæk20 Pharmaceuticals from and for the Global South 298Jean-Paul Gaudillière and Fanny ChabrolPART IV REGULATION AND GOVERNANCE OF PHARMACEUTICALS21 “Regimes of pharmaceutical governance” 315Tineke Kleinhout-Vliek22 Expedited pathways in drug regulation: Evidence, uncertainty, andacceleration in biomedical innovation 324Mathias Møllebæk23 From unmet medical needs to dilemmas of access to treatment: the case ofrare diseases and orphan drugs 337Carlos Novas24 The (ill)logics of patient engagement in drug development and evaluation 349Olga Zvonareva and Hadewych Honné25 Preventing, detecting, and responding to falsified and substandardmedicines 372Raffaella Ravinetto, Amalia Hasnida and Koen Peeters Grietens26 Universal aspirations and contextual decisions: The Essential MedicinesList and Health Technology Assessment 391Tineke Kleinhout-Vliek and Susi GeigerPART V USE AND MISUSE OF PHARMACEUTICALS27 Ecologies of pharmaceutical consumption 408Sarah Wadmann28 De/prescribing matters: Ecologies of prescribing and deprescribing inScience and Technology Studies 419Lisa Lehner, Honja Hama, Igor Grabovac and Janina Kehr29 Ecologies of resistance: The biosocial worlds of antibiotics 442Joyce Sauann Lu and Omar Dewachi30 Precision medicine and the reconfiguration of clinical practice andpatienthood 462Sarah Wadmann, Amalie Martinus Hauge, Anna Brueckner Johansenand Laura Emdal Navne31 Beyond lay pharmacology: Fugitive, alternative, and pluralisticpharmacologies as collective practice 482Magdalena Góralska, Anthony Rizk and Nayantara Sheoran Appleton32 Pharmaceutical leakage: The porous interplay between legal and illegalopioid markets 497Anne M. Lovell and Nancy D. Campbell33 The food challenge to pharma: the unexplored potential of food drugs 512Stephanie A. NairnPART VI AFTERWORD34 Reflections: Pharmaceuticals and biotechnologies through STS lenses 529Sergio Sismondo